Drugs / AAV-hTERT
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04133649 | Oct 2019 → Jan 2021 | — | Libella Gene Therapeutics | Unknown | No outcome recorded |
| Phase 1 | NCT04133454 | Oct 2019 → Jan 2021 | Alzheimer disease | Libella Gene Therapeutics | Unknown | No outcome recorded |
| Phase 1 | NCT04110964 | Sep 2019 → Dec 2020 | limb ischemia | Libella Gene Therapeutics | Unknown | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AAV-hTERT | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04133649 ↗ |
| Known as | LGT | “subjects will receive a single LGT (AAV-hTERT) treatment via IV administration” NCT04133649 ↗ |
| Action | Restore | “Investigate LGT's ability to deliver hTERT to human cells and lengthen telomeres.” NCT04110964 ↗ |
| Modality | Gene therapy (AAV / viral vector) | “This study will entail treating subjects with hTERT delivered via transduction using AAV.” NCT04110964 ↗ |
| Route | Intravenous | “via IV administration” NCT04110964 ↗ |
| Target | TERT | “Using gene therapy to express active telomerase (hTERT) in human cells” NCT04110964 ↗ |